BRCA1 and neoplasm: Further analysis of the Cancer Genome Atlas cohort identified four subtypes, with the C3 subtype having the highest immune signatures, an increased number of tumor-infiltrating immune cells, and a greater expression of immune checkpoints, particularly in patients with the BRCA1 mutation.